With capabilities supporting its next-generation ADC pipeline scaled up externally, Sutro Biopharma’s operations in San Carlos, California will cease this year.
The Biotechnology Innovation Organization’s survey also found nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products.
